Idiopathic Granulomatous Mastitis (IGM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04424615|
Recruitment Status : Not yet recruiting
First Posted : June 11, 2020
Last Update Posted : October 6, 2020
|Condition or disease|
|Idiopathic Granulomatous Mastitis|
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Idiopathic Granulomatous Mastitis|
|Estimated Study Start Date :||October 2020|
|Estimated Primary Completion Date :||October 2021|
|Estimated Study Completion Date :||November 2021|
- clinical response rate [ Time Frame: six months ]
The clinical response is categorized into ''completely healed,'' ''inadequately healed,'' ''stable,'' ''worsened,'' or ''relapsed'' if the lesions had once healed but symptoms returned.
clinical response rate [ Time Frame: six months ] The clinical response is categorized into ''completely healed,'' ''inadequately healed,'' ''stable,'' ''worsened,'' or ''relapsed'' if the lesions had once healed but symptoms returned.
- recurrence rate [ Time Frame: two years ]granulomatous mastitis recurrence
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04424615
|Contact: sherif bakeer, resident firstname.lastname@example.org|